Yogesh Jethava is a Hematology physician affiliated with Johnson & Johnson. OpenAlex indexes 116 publications with 1,809 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1700 Luther Ln Ste 1220
Park Ridge, IL 600681270
Telephone
847-723-4400Provider last certified this registry record 2 May 2025.
Clinical trials
- A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
Sponsor: University of Arkansas
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year202518 payments$17,754openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202510 payments$17,486openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202514 payments$14,089openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
60.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor60.3%Acyclovir100%Part D≥26 patientsAnti-infectives
15.9%Short-acting sulfonamides8.6%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsAzole Antifungal7.3%Voriconazole100%Part D<11 patientsMetabolism & gastrointestinal
8.6%Proton pump inhibitor8.6%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Wayne Drevets, MD
Johnson & Johnson
Matthew Breyer, MD
Johnson & Johnson
Deepu Madduri, MD
Johnson & Johnson
Elliot Barnathan, MD
Johnson & Johnson
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”